



A global leader in non-invasive orthopaedics

April 2021



The big picture



Össur at a glance





Global medical device company

- A global leader in non-invasive orthopaedics
- Operations in more than 27 countries
- ~3,500 full-time employees across the globe



- ~5% of sales invested in R&D with ~1,700 granted patents
- New product launches every year
- Top tier brand recognition based on quality and high reliability



Profitable growth

- Organic and acquisitive sales growth
- 18% sales growth CAGR since listing in 1999
- 22% EBITDA margin in 2019 (15% in 2020)



Shareholders


- Listed on Nasdaq in Copenhagen (Ticker: OSSR)
- Dividends and share buybacks
- International shareholder base






Strong global presence











Key strengths of the Össur business model






We strive to create a Life Without Limitations® for all our users by improving people's mobility





Össur has opportunities for further penetration in both markets





Source: Össur management estimates

Note: Estimates only account for component sales from providers to suppliers, i.e. not clinical services

^{1.} Increased penetration of high-end innovative products

^{2.} Orthotic & Prosthetic clinics

Only 30-40% of all new leg amputees are currently fitted with prosthetic solutions



			Western world	Emerging markets	
>750,000	30-40%	New lower limb amputees per year	~200,000	~550,000	
		Fitted with prosthesis	40-60%	10-30%	
New lower limb amputees per year	of new leg amputees are fitted with prosthetic solutions	Average age	Above 70	Below 70	
		Reason for amputation	Vascular 70-90%	Mainly Trauma	
65-70 is the average age of the amputee population	New lower limb amputations	Growing number of amputees receiving prosthetics		>3% 1% 2005 2010 2015 3 fitted with a prosthesis	
	■Vascular related diseases ■Trauma ■Other		New lower limit		

Source: Össur management estimates

Example of megatrends that provide opportunity for positive development in volume, pricing and product mix for Össur





Aging and more active population

- 1. The global population of 65 and older is increasing, and so is the amputee population
- 2. Growing numbers affected by vascular disease, the leading cause of amputation
- 3. Increased amount of fractures, joint instability and joint afflictions



Increased penetration of high-end solutions

- 1. New innovative technologies being accepted for reimbursement
- 2. Gradual transition from volume to value-based payment in healthcare
- 3. Increased acknowledgement of healthcare economic benefits of bionics and OA bracing



Growing middle class in emerging markets

- 1. Global economic growth will be powered by emerging markets
- 2. Disposable income increasing in emerging markets, willingness to pay out-of-pocket
- 3. Increasing healthcare coverage in emerging markets



Increasing regulatory requirements

- 1. Investments in people and processes to adapt to changing healthcare requirements
- 2. Product development to meet prevailing regulatory requirements
- 3. Increasing importance of digital and personal data security



Increased pressure on healthcare budgets

- 1. Healthcare providers increasing efforts to manage cost
- 2. Demand for cost effective solutions without compromising quality
- 3. Consolidation in patient care



Improved treatment options

- 1. Earlier diabetic detection, limb salvage and alternative treatment options
- 2. Surgery, wound care and easily accessible pain medication provide alternatives to bracing
- 3. Increasing healthcare coverage and better access to patients


Strategic priorities

From simple prosthetics to powered, intelligent and energy efficient bionic solutions



ÖSSUR

There is a need to create solutions that better match the needs of low active amputees



The benefits of high-end solutions

- Reduce risk of falls
- Reduce dependency on others
- Reduce cost in elderly care
- Increase mobility
- Increase daily prosthetic use







From passive feet to energy efficient feet




From socket molding to user-friendly technology

From a mechanical knee to a **powered knee**

Recent studies clearly demonstrate the economic benefit of bionic solutions and their improvement to the quality of life for amputees






Source: * L., Hangsheng, et.al. Economic Value of Advanced Transfemoral Prosthetics. Santa Monica, CA: RAND Corporation, 2017 ** Mundell, et al., 2017

Note: ICER is a statistic used to assess the cost-effectiveness of a health care intervention and is synonymous with the cost per quality-adjusted life year (QALY) gained. Thresholds defined with consensus of the Institute for Clinical and Economic Review, 2017 Even though the emerging markets are a relatively small % of total sales they are an important growth contributor





Össur's O&P Services (OPS) is an offering that strengthens Össur as a business partner










		P&L for an average O&P	clinic in the Unit	ted States			
COST OF GOODS SOLD				G&A			
Cost of goods (Raw materials, fabrication, supply management, freight)		Labor cost Clinical & technical	Office staff salaries	Occupancy	Employee benefits	Other G&A	
29 - 31%		13 - 21%	16 - 23%	6 - 8%	4%	13 - 16%	
43 - 54%			40 - 51%				
Industry average of around 7% profitability and profit leaders with around 15%							
Key trends for O&P clinics		latory contain healthcare co	sts enterp	plex consolidated erations demand orise class systems and processes	profita	d to improve ability without g quality of care	

Partnership Services to support O&P with best practices to increase profitability and drive sales

New generation of products will focus on the seamless integration of technology and human function





CSR and Sustainability

0

Össur has initiatives in place to support the UN Sustainable Development Goals





World goals	Ensure healthy lives and promote well-being for all at all ages	Achieve gender equality and empower all women and girls	Ensure sustainable consumption and production patterns	Take urgent action to combat climate change and its impacts
How Össur will contribute	Improve access to healthcare for amputees	Ongoing commitment towards gender equality	Reducing the environmental footprint of our products	Actively work towards a carbon neutral operation
Example of measurements	 Launch products for elderlies Initiate and/or support clinical investigations 	 Maintain an even employee gender split (+/- 10%) Increase women in management 	 Sustainable product design Reduce material in product packaging 	 Reduce emissions from travel and freight Aim for renewable energy options

A closer look at good health and well-being

3 GOOD HEALTH AND WELL-BEING

Globally, only 30-40% of new lower limb amputees are fitted with a prosthetic solution. The average age of amputees is between 65-70 years and vascular related amputations are above 80% in the developed world. Statistics demonstrate that if amputees in this age group do not become mobile, life-expectancy is materially reduced. Physical activity and exercise can have immediate and long-term health benefits and improve quality of life.

Össur is adding special focus on designing products that support the needs of elderly

1
-

Design and market functional products for the elderly

2

Initiate and/or support clinical investigations focusing on clinical benefits related to more functional products for elderly

3

Engage with industry specialists and decision makers to secure access to more functional products for elderly







We care about the environment and take our responsibility seriously.

We are actively reducing our carbon footprint and to commemorate the Company's 50th anniversary,


Össur will be Carbon Neutral in 2021



Össur has partnered with First Climate, a leading service provider of carbon emissions management, to achieve carbon neutrality.


Carbon neutral for Scope 1 and 2 emissions, and selected Scope 3 emissions

Employee highlights










Össur has grown through a healthy combination of organic growth and acquisitions

Note: Chart is an approximation for split between organic and acquired growth



Össur has a history of strong organic growth, increasing profitability and strong cash flow






*EBITDA before special items in 2018 and 2019


Impact from M&A activity in 2019 & 2020



Organic sales growth/decline



EBITDA margin before special items



Financial impact

- Sales increasing by ~10 MUSD using 2019 as a reference year not impacted by COVID-19
- Positive impact on organic growth with ~1 p.p. increase on 2019 figures and positive impact of ~0.6 p.p. in 2020
- GPM stable between reported and proforma figures
- EBITDA margin increasing by ~100 basis points
- B&S sales would have been 38% of total sales (reported 45%) in 2019 and 36% (reported 41%) in 2020



Initiative	Description	Cumulative savings		
Distribution	Close a distribution facility and move its operations to the Mexico manufacturing facility to harvest scale and efficiency	USD million Realized		~10
Manufacturing	Move a part of the prosthetics manufacturing from Iceland to the Mexico manufacturing facility Close Össur's largest US manufacturing facility in Albion and move its activities to Mexico		~6	
Strategic sourcing	Establish a centralized strategic sourcing department to harvest savings across key spend categories	~3 2017 2018	2019	2020

Note: Össur announced efficiency initiatives in September 2017. For further information see company announcement no. 68/2017.

Savings by moving certain distribution and manufacturing activities to a low-cost environment

#	Action	Impact
1	Close distribution facility in the US and move activities to Mexico	1 less site 20 new postitions in Mexico
2	Move part of prosthetics manufacturing from Iceland to Mexico	60 new positions in Mexico
3	Close down manufacturing site in the US and move activities to Mexico	1 less site 30 new positions in Mexico
Tota	al	2 less sites 110 new positions in Mexico





We have an increasingly scalable infrastructure


Category	Scalability	Key drivers impacting profitability
COGS	High	 Scalable manufacturing platform Centralized procurement (strategic sourcing) 12 fewer locations since 2009
S&M	Medium	 Implementation of a new CRM platform Growing bionics sales Össur's O&P Services Investments in market access in emerging markets
G&A	High	 Shared service center in Poland supporting around 60% Össur's entities Investments in global IT which is supporting majority of Össur's entities
R&D	Low	Investments in high-end product developmentNew innovation such as exoskeletons




of

Illustration of expected EBITDA margin development in the short- to medium-term





With a strong cash flow generation and capital structure, Össur began returning capital to shareholders via buybacks and dividends in 2013




FCF **~85% of EBIT** on average


Target

1.5-2.5x

NIBD/EBITDA

Net interest-bearing debt





Total of USD 235 million since 2013





Forward-looking statement

This presentation contains forward-looking statements, which reflect the Management's current views with respect to certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there is no assurance that these statements will be achieved.

Statements containing the financial outlook for 2021 and the following years naturally involve risks and uncertainties, and consequently actual results will differ, and may differ materially, from those projected or implied in the forward-looking statements.

The risks and uncertainties may include unexpected developments in the international currency exchange and securities markets, financing, market driven price decreases for Össur's products, delay or failure of development products, products, production problems and unexpected cost increases, development of new technologies by competitors, the introduction of competing products within Össur's core areas, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws.